Paraneoplastic neurological disorders

Steven Vernino, Josep Dalmau

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Paraneoplastic neurological disorders (PNDs) are rare, often devastating, autoimmune disorders affecting any part of the nervous system. PNDs have an autoimmune etiology, but the details of the pathogenesis are not fully known. Further, the pathophysiology appears to differ from one disorder to another. PNDs were first clinically recognized several years ago with descriptions of sensory neuronopathy, limbic encephalitis, and cerebellar degeneration in patients with cancer. PND appears to represent an aberrant manifestation of an effective antitumor immune response. There are two aspects of the pathogenesis of PND: (1) the generation of a vigorous immune response to cancer and (2) a break in immune tolerance that allows this response to target the nervous system. PND can be divided into two groups based on the type of associated autoantibodies. The first group of antibodies that may be associated with PND is antibodies against cell surface antigens, including neuronal ion channels. The second and larger group consists of antibodies directed against intracellular antigens in the nucleus or cytoplasm of neurons. The symptoms of PND vary and follow from the area of the nervous system affected. The loss of Purkinje cells in paraneoplastic cerebellar degeneration results in severe cerebellar ataxia. The loss of dorsal root ganglia cells in paraneoplastic sensory neuronopathy results in profound sensory loss, sensory ataxia, and pseudoathetosis.

Original languageEnglish (US)
Title of host publicationNeurobiology of Disease
PublisherElsevier Inc.
Pages163-169
Number of pages7
ISBN (Print)9780120885923
DOIs
StatePublished - 2007

Fingerprint

Nervous System Diseases
Nervous System
Antibodies
Paraneoplastic Cerebellar Degeneration
Limbic Encephalitis
Cerebellar Ataxia
Immune Tolerance
Purkinje Cells
Spinal Ganglia
Ataxia
Surface Antigens
Ion Channels
Autoantibodies
Neoplasms
Cytoplasm
Neurons
Antigens

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)

Cite this

Vernino, S., & Dalmau, J. (2007). Paraneoplastic neurological disorders. In Neurobiology of Disease (pp. 163-169). Elsevier Inc.. https://doi.org/10.1016/B978-012088592-3/50017-7

Paraneoplastic neurological disorders. / Vernino, Steven; Dalmau, Josep.

Neurobiology of Disease. Elsevier Inc., 2007. p. 163-169.

Research output: Chapter in Book/Report/Conference proceedingChapter

Vernino, S & Dalmau, J 2007, Paraneoplastic neurological disorders. in Neurobiology of Disease. Elsevier Inc., pp. 163-169. https://doi.org/10.1016/B978-012088592-3/50017-7
Vernino S, Dalmau J. Paraneoplastic neurological disorders. In Neurobiology of Disease. Elsevier Inc. 2007. p. 163-169 https://doi.org/10.1016/B978-012088592-3/50017-7
Vernino, Steven ; Dalmau, Josep. / Paraneoplastic neurological disorders. Neurobiology of Disease. Elsevier Inc., 2007. pp. 163-169
@inbook{4e3f6e915be745b28c95cbb810aea67e,
title = "Paraneoplastic neurological disorders",
abstract = "Paraneoplastic neurological disorders (PNDs) are rare, often devastating, autoimmune disorders affecting any part of the nervous system. PNDs have an autoimmune etiology, but the details of the pathogenesis are not fully known. Further, the pathophysiology appears to differ from one disorder to another. PNDs were first clinically recognized several years ago with descriptions of sensory neuronopathy, limbic encephalitis, and cerebellar degeneration in patients with cancer. PND appears to represent an aberrant manifestation of an effective antitumor immune response. There are two aspects of the pathogenesis of PND: (1) the generation of a vigorous immune response to cancer and (2) a break in immune tolerance that allows this response to target the nervous system. PND can be divided into two groups based on the type of associated autoantibodies. The first group of antibodies that may be associated with PND is antibodies against cell surface antigens, including neuronal ion channels. The second and larger group consists of antibodies directed against intracellular antigens in the nucleus or cytoplasm of neurons. The symptoms of PND vary and follow from the area of the nervous system affected. The loss of Purkinje cells in paraneoplastic cerebellar degeneration results in severe cerebellar ataxia. The loss of dorsal root ganglia cells in paraneoplastic sensory neuronopathy results in profound sensory loss, sensory ataxia, and pseudoathetosis.",
author = "Steven Vernino and Josep Dalmau",
year = "2007",
doi = "10.1016/B978-012088592-3/50017-7",
language = "English (US)",
isbn = "9780120885923",
pages = "163--169",
booktitle = "Neurobiology of Disease",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Paraneoplastic neurological disorders

AU - Vernino, Steven

AU - Dalmau, Josep

PY - 2007

Y1 - 2007

N2 - Paraneoplastic neurological disorders (PNDs) are rare, often devastating, autoimmune disorders affecting any part of the nervous system. PNDs have an autoimmune etiology, but the details of the pathogenesis are not fully known. Further, the pathophysiology appears to differ from one disorder to another. PNDs were first clinically recognized several years ago with descriptions of sensory neuronopathy, limbic encephalitis, and cerebellar degeneration in patients with cancer. PND appears to represent an aberrant manifestation of an effective antitumor immune response. There are two aspects of the pathogenesis of PND: (1) the generation of a vigorous immune response to cancer and (2) a break in immune tolerance that allows this response to target the nervous system. PND can be divided into two groups based on the type of associated autoantibodies. The first group of antibodies that may be associated with PND is antibodies against cell surface antigens, including neuronal ion channels. The second and larger group consists of antibodies directed against intracellular antigens in the nucleus or cytoplasm of neurons. The symptoms of PND vary and follow from the area of the nervous system affected. The loss of Purkinje cells in paraneoplastic cerebellar degeneration results in severe cerebellar ataxia. The loss of dorsal root ganglia cells in paraneoplastic sensory neuronopathy results in profound sensory loss, sensory ataxia, and pseudoathetosis.

AB - Paraneoplastic neurological disorders (PNDs) are rare, often devastating, autoimmune disorders affecting any part of the nervous system. PNDs have an autoimmune etiology, but the details of the pathogenesis are not fully known. Further, the pathophysiology appears to differ from one disorder to another. PNDs were first clinically recognized several years ago with descriptions of sensory neuronopathy, limbic encephalitis, and cerebellar degeneration in patients with cancer. PND appears to represent an aberrant manifestation of an effective antitumor immune response. There are two aspects of the pathogenesis of PND: (1) the generation of a vigorous immune response to cancer and (2) a break in immune tolerance that allows this response to target the nervous system. PND can be divided into two groups based on the type of associated autoantibodies. The first group of antibodies that may be associated with PND is antibodies against cell surface antigens, including neuronal ion channels. The second and larger group consists of antibodies directed against intracellular antigens in the nucleus or cytoplasm of neurons. The symptoms of PND vary and follow from the area of the nervous system affected. The loss of Purkinje cells in paraneoplastic cerebellar degeneration results in severe cerebellar ataxia. The loss of dorsal root ganglia cells in paraneoplastic sensory neuronopathy results in profound sensory loss, sensory ataxia, and pseudoathetosis.

UR - http://www.scopus.com/inward/record.url?scp=84884044248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884044248&partnerID=8YFLogxK

U2 - 10.1016/B978-012088592-3/50017-7

DO - 10.1016/B978-012088592-3/50017-7

M3 - Chapter

AN - SCOPUS:84884044248

SN - 9780120885923

SP - 163

EP - 169

BT - Neurobiology of Disease

PB - Elsevier Inc.

ER -